LLY

1,136.74

+4.61%↑

JNJ

227.5

+1.33%↑

ABBV

222.33

+1.68%↑

UNH

395.67

+3.16%↑

MRK

119.04

+2.72%↑

LLY

1,136.74

+4.61%↑

JNJ

227.5

+1.33%↑

ABBV

222.33

+1.68%↑

UNH

395.67

+3.16%↑

MRK

119.04

+2.72%↑

LLY

1,136.74

+4.61%↑

JNJ

227.5

+1.33%↑

ABBV

222.33

+1.68%↑

UNH

395.67

+3.16%↑

MRK

119.04

+2.72%↑

LLY

1,136.74

+4.61%↑

JNJ

227.5

+1.33%↑

ABBV

222.33

+1.68%↑

UNH

395.67

+3.16%↑

MRK

119.04

+2.72%↑

LLY

1,136.74

+4.61%↑

JNJ

227.5

+1.33%↑

ABBV

222.33

+1.68%↑

UNH

395.67

+3.16%↑

MRK

119.04

+2.72%↑

Home・Akcijų sąrašas・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Atidarymo kaina

SektoriusSveikatos priežiūra

11.17 -0.53

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.56

Max

11.27

Pagrindiniai rodikliai
By Trading Economics
Pajamos	227M
Pardavimai	139M
P/E Sektoriaus vid.	4.302 49.888
Pelno marža	163.843
Darbuotojai	1,796
EBITDA	1.3M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+45.83% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2B
Ankstesnė atidarymo kaina	11.7
Ankstesnė uždarymo kaina	11.17

Naujienos nuotaikos

By Acuity

10%

90%

9 / 344 reitingas Healthcare

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-03 23:22; UTC

Uždarbis

Pagrindinės rinkos jėgos

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

2026-06-03 23:09; UTC

Karštos akcijos

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

2026-06-03 20:51; UTC

Uždarbis

Costco Reports 15% Sales Growth in May

2026-06-03 20:43; UTC

Uždarbis

Broadcom 2Q Revenue Climbs on AI Chip Demand

2026-06-03 23:48; UTC

Rinkos pokalbiai

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

2026-06-03 23:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-03 23:35; UTC

Rinkos pokalbiai

Oil Futures Fall on Possible Technical Correction -- Market Talk

2026-06-03 23:15; UTC

Rinkos pokalbiai

Uždarbis

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

2026-06-03 22:08; UTC

Karštos akcijos

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

2026-06-03 21:54; UTC

Rinkos pokalbiai

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

2026-06-03 21:18; UTC

Uždarbis

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

2026-06-03 21:15; UTC

Uždarbis

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

2026-06-03 21:13; UTC

Uždarbis

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

2026-06-03 21:13; UTC

Uždarbis

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

2026-06-03 21:12; UTC

Uždarbis

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

2026-06-03 21:09; UTC

Uždarbis

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

2026-06-03 21:03; UTC

Uždarbis

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

2026-06-03 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-03 20:43; UTC

Uždarbis

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

2026-06-03 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

2026-06-03 20:37; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

2026-06-03 20:35; UTC

Uždarbis

Broadcom Stock Falls Despite Record Results -- Barrons.com

2026-06-03 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

2026-06-03 20:17; UTC

Uždarbis

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

2026-06-03 20:17; UTC

Uždarbis

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

2026-06-03 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

2026-06-03 20:15; UTC

Uždarbis

Broadcom 2Q Adj EPS $2.44 >AVGO

2026-06-03 20:15; UTC

Uždarbis

Broadcom 2Q EPS $1.91 >AVGO

2026-06-03 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-03 20:15; UTC

Uždarbis

Broadcom 2Q Rev $22.19B >AVGO

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

45.83% į viršų

12 mėnesių prognozė

Vidutinis 16.8 USD 45.83%

Aukščiausias 20 USD

Žemiausias 13.6 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Hutchison China MediTech Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

9 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.